Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lucely Cetina-Pérez has a total of 123 co-authors. Here are the top co-authors by number of shared publications:

  • Denisse Castro-Eguiluz

    Investigadores por México, Secretaría de Ciencia, Humanidades, Tecnología e Innovación—Department of Clinical Research, Instituto Nacional de Cancerología, Mexico City 03940, Mexico

    8 shared publications
  • Julissa Luvián-Morales

    Subdirección de Investigación Clínica, Programa MICAELA, INCan, Mexico

    4 shared publications
  • Denisse Castro-Eguiluz

    Department of Clinical Research Instituto Nacional de Cancerología Mexico City

    3 shared publications
  • Eder Arango-Bravo

    Department of Clinical Research, Instituto Nacional de Cancerología, Mexico City, Mexico

    3 shared publications
  • Tatiana Galicia-Carmona

    Integral Program for the Care of Locally Advanced and Metastatic Cervical Cancer Instituto Nacional de Cancerología Mexico City

    3 shared publications
  • Julissa Luvián-Morales

    Integral Program for the Care of Locally Advanced and Metastatic Cervical Cancer Instituto Nacional de Cancerología Mexico City

    2 shared publications

Latest Publications

  • Open Access

    The Evolving Role of Radiation Oncology in the Management of Uterine Cervical Carcinoma: A State-of-the-Art Review for Non-Radiation Oncologists

    by Christian Haydeé Flores-Balcázar, Shuhey Augusto Matsumoto-Palomares, Diego Iván Chávez-Zaldívar, Adamary Itai Marin-Trinidad, Francisco Gerardo Castro-Pérez, Lucely del Carmen Cetina-Pérez

    Cervical cancer is one of the most common gynecological tumors globally. When diagnosed, treatment decisions should be based on a risk–benefit analysis of each treatment modality to obtain a cure with minimum complications. The optimal approach for management should consider clinical factors such as age, menopausal status, medical comorbidities, histological type, tumor size, and the extent of disease. Radiotherapy is the cornerstone for successful management in almost all clinical stages of this disease. Options for primary treatment in patients with early cervical cancer may include radical hysterectomy, fertility-sparing surgery, and postoperative radiotherapy with or without platinum-based chemotherapy (CT) according to pathology specimen findings. For locally advanced cervical cancer, chemoradiotherapy has been the standard of care based on the results of clinical trials that showed an overall survival (OS) advantage when adding cisplatin to radiotherapy. After chemoradiotherapy, a cervical boost is mandatory for increased local control and better survival. For metastatic or recurrent cervical cancer, the treatment approach is tailored according to symptoms and performance status. As many techniques and new technologies are available to decrease toxicity while improving the therapeutic ratio, it becomes necessary to collate the current evidence that most effectively enables clinicians to make informed decisions in the management of cervical cancer patients.


  • Top Cited Papers
    Open Access

    Machine and Deep Learning for the Diagnosis, Prognosis, and Treatment of Cervical Cancer: A Scoping Review

    by Blanca Vazquez, Mariano Rojas-García, Jocelyn Isabel Rodríguez-Esquivel, Janeth Marquez-Acosta, Carlos E. Aranda-Flores, Lucely del Carmen Cetina-Pérez, Susana Soto-López, Jesús A. Estévez-García, Margarita Bahena-Román, Vicente Madrid-Marina, et al.

    Background/Objectives: Cervical cancer (CC) is the fourth most common cancer among women worldwide. This study explored the use of machine learning (ML) and deep learning (DL) in the prediction, diagnosis, and prognosis of CC. Methods: An electronic search was conducted in the PubMed, IEEE, Web of Science, and Scopus databases from January 2015 to April 2025 using the search terms ML, DL, and uterine cervical neoplasms. A total of 153 studies were selected in this review. A comprehensive summary of the available evidence was compiled. Results: We found that 54.9% of the studies addressed the application of ML and DL in CC for diagnostic purposes, followed by prognosis (22.9%) and an incipient focus on CC treatment (22.2%). The five countries where most ML and DL applications have been generated are China, the United States, India, Republic of Korea, and Japan. Of these studies, 48.4% proposed a DL-based approach, and the most frequent input data used to train the models on CC were images. Conclusions: Although there are results indicating a promising application of these artificial intelligence approaches in oncology clinical practice, further evidence of their validity and reproducibility is required for their use in early detection, prognosis, and therapeutic management of CC.


  • Top Cited Papers
    Open Access

    Ultrasensitive detection and tracking of circulating tumor DNA to predict relapse and survival in patients with locally advanced cervical cancer: phase III CALLA trial analyses

    by J. Mayadev, J.C. Vázquez Limón, F.J. Ramírez Godinez, M. Leiva, L.D.C. Cetina-Pérez, S. Varga, A. Molina Alavez, A.E. Alarcon-Rozas, N. Valdiviezo, C. Acevedo, et al.


  • Open Access

    Editorial: Cervical cancer: updates from the Mexican national consensus

    by Lucely Cetina-Pérez, Oscar Medina-Contreras

    Human papillomavirus (HPV) is a prevalent virus that poses a significant burden on low-and middle-income countries, particularly among women. Its high prevalence leads to a substantial public health issue and strains healthcare systems worldwide. In response, the World Health Organization launched a global strategy in 2020 to expedite the elimination of cervical cancer (CC). Recognizing the severity of the problem, experts from the Mexican National Cancer Institute (NCI) assembled a multidisciplinary team to develop the National Consensus on Cervical Cancer (2023 update). These comprehensive consensus documents provide evidence-based recommendations for the medical community encompassing epidemiology, diagnosis, screening, treatment, immunotherapy, and prevention of CC, tailored to the specific context of México. It serves as a valuable resource for practitioners caring for adult patients, excluding the pediatric population.A modified Delphi process was employed, involving a general coordinator, 13 coordinators, and 62 experts in the relevant fields. An exhaustive search was conducted on PubMed using the search term "cervical cancer" combined with the keywords Epidemiology, Molecular Biology, Pathology, Prevention, Screening, Early Stage, Locally Advanced, Advanced Cancer, Immunotherapy, Histology, Probiotics, Mental Disease, Pain, and Radiotherapy. The search covered the period from January 2020 to April 2023. All publications were retrieved and reviewed by all consensus members. Evidence quality and Recommendations were assessed using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system (Table 1).Coordinators developed 50 statements and voted anonymously on their content and quality using a Likert scale (totally agree, agree, uncertain, partially disagree, totally disagree). Statements with a total agree score >75% were retained unchanged. Statements with a total disagree score >75% were eliminated. Statements with a total agree or total disagree score 75% approval were ratified, and statements with a <75% approval were discussed to reach a consensus or to eliminate them. After all statements were voted, all participants redacted, reviewed, and approved their manuscripts. Interestingly, they highlight a new link between the number of HPV DNA integrations and the cervical lesions. They also suggest new functions for the classical proteins E5, E6, and E7. Further, the integration from genome, transcriptome, proteome, metabolome, and epigenome information provides novel molecular traits and potential biomarkers and therapeutic targets. Pérez-Montiel et al. discuss the recent advancements in cervical neoplasias classification, and their impact on treatment choices, to improve diagnostic accuracy, and prognostic assessment.González-Rodríguez et al. review preventive measures, focusing on effectiveness, long-term protection, and safety of HPV vaccination programs. They show long-term protection and safety worldwide, using the available vaccines (bivalent, quadrivalent, and nonavalent) reaching a 54%-83% decrease in high-grade cervical abnormalities and genital warts. Still, income disparities and vaccine availability are the main obstacle. Strong against the intervention 1 not initiate or rarely undergo screening. They propose cytology-based screening strategies for accurately identifying women at a higher risk of cervical cancer and establishing screening times. New detection tools, such as novel biomarkers or automatic HPV detection in the vagina or urine, can improve screening coverage. Arango-Bravo et al. summarize the current scientific evidence to formulate clinical recommendations regarding the classification, diagnostic approach, and treatment of rare histological subtypes of cervical cancer. The authors focus in a multimodal approach as critical for treatment in tumors with special histologies.Surgery is the first choice in the early stages of CC, as reviewed by Nájera-Muñoz et al. Despite being a radical procedure, hysterectomy is the standard treatment, but rely on the need to preserve fertility.

  • Open Access

    Sociodemographic characteristics and their association with survival in women with cervical cancer

    by Lucely Cetina-Pérez, Julissa Luvián-Morales, Merari Delgadillo-González, Denisse Castro-Eguiluz, Tatiana Galicia-Carmona, Kely Rely, Rita Vaca González, Gabriela Lugo-Martínez, Nadia García-Barrientos, Antonio Nateras

    Background: In 2020, the highest incidence and mortality from cervical cancer (CC) were detected in low and middle-income countries. CC remains a health problem for women living in them. In Mexico, CC ranks second in cancer incidence and mortality in women. The main characteristics of this population are low income, low educational level, and inadequate medical coverage. The present study characterized the Mexican population by CC, and the sociodemographic variables that impacted overall survival (OS) were identified. Methods: A retrospective study that included a cohort of patients with a confirmed diagnosis of CC at the Instituto Nacional de Cancerologia between 2003 and 2016. Information was collected on sociodemographic variables related to the disease and OS. Results: Four thousand six hundred thirty-one patients were included. The median age was 51 years, 78.5% were unemployed, 44.4% lived in a rural/suburban area, 50.8% had a partner when collecting this information, and 74.3% were classified as having low socioeconomic status. Age, living in a rural/suburban area, more advanced stages of the disease, and not receiving cancer treatment were associated with lower OS. Conclusion: CC continues to affect mainly women with minimal resources, low educational levels, and living in marginalized areas. These characteristics influence the OS. Prevention and timely detection programs, education, and training focused on this population and with broader coverage are required to identify patients with CC at earlier stages.


  • Quality of life but not cachexia definitions are associated with overall survival in women with cervical cancer: a STROBE-compliant cohort study

    by Julissa Luvián-Morales, Merari Delgadillo-González, Denisse Castro-Eguiluz, Luis F Oñate-Ocaña, Lucely Cetina-Pérez

    Cancer-related cachexia (CRC) has a profound impact on health-related quality of life (HRQL), and both were reported to be associated with overall survival (OS). We hypothesize that HRQL and CRC are associated with OS. This study analyzed the impact of CRC on HRQL and its prognostic value in women with cervical cancer (CC). A cohort study including consecutive women with CC treated from October 2020 to October 2021 in a cancer center. Cox’s model defined the associations of immune, biochemical and nutritional parameters, clinical cachexia classifications and HRQL with OS. Two hundred forty-four consecutive women with CC were included. Cachexia classifications and several scales of the QLQ-C30 were associated with OS by bivariate but not by multivariate analysis. QLQ-CX24 scales were not associated with OS. The prognostic nutritional index (PNI) (hazard ratio (HR) 0.828; 95% confidence interval (CI) 0.766–0.896), Food aversion (HR 0.95; 95% CI 0.924–0.976), Eating difficulties (HR 1.041; 95% CI 1.013–1.071), Loss of control (HR 4.131; 95% CI 1.317–12.963), Forced self to eat (1.024; 95% CI 1.004–1.044) and Indigestion (HR 0.348; 95% CI 0.131–0.928) scales of the QLQ-CAX24 were independently associated with OS by multivariate analysis (p = 1.9×10−11). This model permitted a clear stratification of prognostic subgroups. The PNI and several QLQ-CAX24 scales were associated with OS in women with CC. CRC, defined by several cachexia classifications, was not an independent prognostic factor. These findings require confirmation because of their possible diagnostic, therapeutic and prognostic implications.


  • Open Access

    Resources and management for cervical cancer care are insufficient in public hospitals in Mexico

    by Lucely Cetina-Pérez, Julissa Luvián-Morales, Denisse Castro-Eguiluz, Tatiana Galicia-Carmona, Silvia E. Alarcón-Barrios, Eder A. Arango-Bravo, Samuel Rivera-Rivera, Gregorio Quintero-Beuló, Dolores Gallardo-Rincón, Vicente Madrid-Marina

    Background: Information on the resources available for treating cervical cancer (CC) in the Mexican health-care system is unavailable. Objective: To describe the resources available to treat CC in Mexican public institutions. Methods: A survey was applied to members from Mexican Societies of Oncology and Radio-oncology. Results: Five hundred and six surveys were analyzed, identifying the following: to diagnose, 96.2% of institutions had computed tomography. The time between diagnosis of CC and treatment was frequently 5-8 weeks. Sixty percentages of institutions had access to radiotherapy. Most institutions had pathology and psychology services, and few had nutrition and algology. Most specialists chose open surgery to treat early-stage CC. Treatment for locally advanced stages was concomitant chemoradiation. Very few specialists had access to vinorelbine, topotecan, and bevacizumab. Up to 20% of patients abandon their treatment. Conclusion: The resources and infrastructure for the care and treatment of CC patients are limited in the Mexican health-care system.

  • Chemoradiotherapy treatment with gemcitabine improves renal function in locally advanced cervical cancer patients with renal dysfunction

    by Silvia Alarcón-Barrios, Julissa Luvián-Morales, Denisse Castro-Eguiluz, Merari Delgadillo-González, Brenda Olivia Lezcano-Velázquez, Eder Alexandro Arango-Bravo, Laura Flores-Cisneros, Sebastián Aguiar Rosas, Lucely Cetina-Pérez

  • Open Access

    Effect of a fermented dairy beverage on treatment-related toxicity and inflammation in locally advanced cervical cancer patients, a randomized placebo-controlled pilot study.

    by Denisse Castro-Eguiluz, Julissa Luvián Morales, Merari Delgadillo González, Clementina Castro Hernández, Aurora Espejel Núñez, Lesbia María Rivera Rubí, Alejandra Rueda Escalona, Christian Aguila Mancera, María Guadalupe Serna Thomé, Lucely Cetina-Pérez

    Purpose. This study aimed to analyze the effect of a probiotic-rich fermented dairy beverage, compared to a placebo, on gastrointestinal toxicity, inflammatory response, chronic toxicity, and quality of life, in locally advanced cervical cancer (LACC) patients. Methods. A randomized, double blind, placebo-controlled pilot study assigned LACC patients to the probiotic group (n=21) or the placebo group (n=21). Intervention with probiotic or placebo beverage began 2 weeks before treatment through 90 days after treatment. The frequency and severity of toxicity symptoms, nutritional parameters, serum cytokines, fecal calprotectin, proctopathy, and quality of life were evaluated throughout treatment. Results.Lower frequency and severity of vomit were observed in the probiotic group compared to placebo (15% vs 40%, p=0.03). No differences were observed in the frequency of symptoms among groups, including diarrhea. A trend was observed toward lower levels of inflammatory cytokines in the probiotic group. No significant differences were observed in the development of proctopathy. Conclusion.This study demonstrated the fermented dairy beverage’s beneficial effect on reducing the frequency and severity of vomit and a tendency to lower inflammation. Still, it did not provide benefits regarding other treatment-related toxicities, probably due to the small sample size. Trial Registration Number NCT05736315, retrospectively registered on February 16, 2023.

  • Open Access

    Effectiveness of Concomitant Chemoradiotherapy with Gemcitabine in Locally Advanced Cervical Cancer Patients with Comorbidities

    by Hasan Brau-Figueroa, Eder Arango-Bravo, Denisse Castro-Eguiluz, Tatiana Galicia-Carmona, Leopoldo Abraham Lugo-Alferez, Ivette Cruz-Bautista, Roberto Jiménez-Lima, Lucely Cetina-Pérez

    PurposeThe standard treatment for locally advanced cervical cancer (LACC) is concomitant chemoradiotherapy with cisplatin (CDDP) followed by brachytherapy. The presence of comorbidities are risk factors for nephrotoxicity and are associated with lower survival. Gemcitabine is a radiosensitizing drug that has shown efficacy and safety in this context. The effectiveness of concomitant chemoradiotherapy with gemcitabine was evaluated versus cisplatin in LACC patients with comorbidities and preserved renal function. Materials and MethodsAn observational, longitudinal and paired study was carried out that included patients treated between February 2003 and December 2015. The primary objectives were to evaluate response rates, progression-free survival, and overall survival; the secondary objectives were to evaluate toxicity and renal function. ResultsSixty-three patients treated with gemcitabine at 300 mg/m2 weekly and 126 patients treated with CDDP 40 mg/m2 weekly were included. There were no significant differences in response rates and survival rates. Treatment with cisplatin presented a higher frequency of hematological toxicities, while gemcitabine presented a higher frequency of gastrointestinal toxicities. A decrease in glomerular filtration rate (GFR; baseline vs. 1-year post-treatment) was observed in the cisplatin group (p=0.002), while not in the gemcitabine group (p=0.667). In a multivariate analysis, it is observed that only CDDP correlates with the decrease in GFR (hazard ratio, 2.42; p=0.012).ConclusionIn LACC patients with comorbidities, gemcitabine and CDDP show the same efficacy, with different toxicity profiles. Treatment with cisplatin is associated with a significant decrease in GFR during follow-up, compared to treatment with gemcitabine that does not decrease it.